Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 253-260

  Reitter, E M ^a   Ay, C ^a   Kaider, A ^a   Pirker, R ^b   Zielinski, C ^b   Zlabinger, G ^a   Pabinger, I ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Interleukin levels; Survival; Thrombosis

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BRAIN CANCER; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; COLON CARCINOMA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SARCOMA; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; VENOUS THROMBOEMBOLISM;

CANCER; INTERLEUKIN LEVELS; SURVIVAL; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VENOUS THROMBOEMBOLISM;

EID: 84904240547     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12308     Document Type: Article

References (49)

1. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol 2007; 189:162-170.
2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5:632-634.
3. Lyman GH, Khorana AA, Falanga A etal. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490-5505.
4. Gao S, Escalante C. Venous thromboembolism and malignancy. Exp Rev Anticancer Ther 2004; 4:303-320.
5. Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol 2011; 37:1072-1077.
6. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117:1334-1349.
7. Martin LK, Bekaii-Saab T. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? Thrombosis 2012; 2012:758385.
8. Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010; 8:1702-1709.
9. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLOS Med 2012; 9:e1001275.
10. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-815.
11. Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hamostaseologie 2009; 29:121-124.
12. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722.
13. Kanz R, Vukovich T, Vormittag R etal. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9:57-63.
14. Vormittag R, Simanek R, Ay C etal. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29:2176-2181.
15. Ay C, Simanek R, Vormittag R etal. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703-2708.
16. Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012; 129 (Suppl. 1):S6-S9.
17. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102 (Suppl. 1):S2-S9.
18. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004; 2:2107-2114.
19. Vormittag R, Hsieh K, Kaider A etal. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G > C in patients with spontaneous venous thromboembolism. Thromb Haemost 2006; 95:802-806.
20. Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 2013; 39:89-96.
21. Orditura M, De VF, Catalano G etal. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002; 22:1129-1135.
22. Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M. CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38-41.
23. Wang YC, Sung WW, Wu TC etal. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLOS ONE 2012; 7:e39525.
24. Yanagawa H, Sone S, Takahashi Y etal. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71:1095-1098.
25. Heikkila K, Harris R, Lowe G etal. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20:15-26.
26. Songur N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004; 90:196-200.
27. De VF, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5:649-652.
28. De VF, Romano C, Orditura M etal. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001; 21:45-52.
29. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997; 33:1794-1798.
30. Chang CH, Hsiao CF, Yeh YM etal. Circulating interleukin-6 level is a prognostic marker for survival in advanced non-small cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977-1985.
31. Guan E, Wang J, Norcross MA. Identification of human macrophage inflammatory proteins 1alpha and 1beta as a native secreted heterodimer. J Biol Chem 2001; 276:12404-12409.
32. Malaponte G, Polesel J, Candido S etal. IL-6-174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine 2013; 62:64-69.
33. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLOS Med 2006; 3:e334.
34. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116:173-177.
35. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117:3660-3663.
36. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904-910.
37. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 2010; 88:1109-1117.
38. Chang CH, Hsiao CF, Yeh YM etal. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132:1977-1985.
39. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3:791-800.
40. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226:205-218.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
42. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218-e228.
43. Galizia G, Orditura M, Romano C etal. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102:169-178.
44. Salgado R, Junius S, Benoy I etal. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642-646.
45. Nakashima J, Tachibana M, Horiguchi Y etal. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6:2702-2706.
46. Martin F, Santolaria F, Batista N etal. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-86.
47. Kaminska J, Kowalska M, Kotowicz B etal. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology 2006; 70:115-125.
48. De VF, Orditura M, Galizia G etal. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000; 117:365-373.
49. Baune BT, Rothermundt M, Ladwig KH, Meisinger C, Berger K. Systemic inflammation (interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. Age (Dordr) 2011; 33:209-217.